Skip to main content
SpringerLink
Log in

Anthelmintics in Dermatology

  • Chapter
  • First Online:
Biologic and Systemic Agents in Dermatology

  • 1509 Accesses

Abstract

Permethrin and ivermectin are among the most commonly used topical agents for scabies. Permethrin topical 5% cream is the first-line treatment, and should be applied to the entire skin surface from the neck-down. Most practitioners advise patients to apply the entire tube of 30 g at bedtime and leave it in place all night. In the morning patients should wash all bedding and clothing in hot water and then bathe. For all scabies infestations, this process should be repeated 1 week later at the very least; additional weekly applications are frequently necessary for “Norwegian”/crusted scabies [1, 2]. Permethrin is generally well tolerated, occasionally associated with mild skin irritation, and exists as a treatment option for pregnant women [3, 4].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  1. Andrews RM, McCarthy J, Carapetis JR, Currie BJ. Skin disorders, including pyoderma, scabies, and tinea infections. Pediatr Clin N Am. 2009;56(6):1421–40.

    Article  Google Scholar 

  2. Strong M, Johnstone P. Interventions for treating scabies. Cochrane Database Syst Rev. 2007;3:CD000320.

    Google Scholar 

  3. Hay RJ. Scabies and pyodermas—diagnosis and treatment. Dermatol Ther. 2009;22(6):466–74.

    Article  CAS  PubMed  Google Scholar 

  4. Burns T, Breathnach S, Cox N, Griffiths C. Rook’s textbook of dermatology. 8th ed. Hoboken, NJ: Wiley-Blackwell; 2010.

    Book  Google Scholar 

  5. Panahi Y, Poursaleh Z, Goldust M. The efficacy of topical and oral ivermectin in the treatment of human scabies. Ann Parasitol. 2015;61(1):11–6.

    PubMed  Google Scholar 

  6. Orzechowski KL, Swain MD, Robl MG, et al. Neurotoxic effects of ivermectin administration in genetically engineered mice with targeted insertion of the mutated canine ABCB1 gene. Am J Vet Res. 2012;73(9):1477–84.

    Article  CAS  PubMed  Google Scholar 

  7. Burkhart CN, Burkhart CG. Ivermectin: a few caveats are warranted before initiating therapy for scabies. Arch Dermatol. 1999;135(12):1549–50.

    Article  CAS  PubMed  Google Scholar 

  8. Allinson J, Topping W, Edwards SG, Miller RF. Sulphadiazine-induced obstructive renal failure complicating treatment of HIV-associated toxoplasmosis. Int J STD AIDS. 2012;23(3):210–2.

    Article  CAS  PubMed  Google Scholar 

  9. Edwards G. Ivermectin: does P-glycoprotein play a role in neurotoxicity? Filaria J. 2003;2(Suppl 1):S8.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Pacqué M, Muñoz B, Poetschke G, Foose J, Greene BM, Taylor HR. Pregnancy outcome after inadvertent ivermectin treatment during community-based distribution. Lancet. 1990;336(8729):1486–9.

    Article  PubMed  Google Scholar 

  11. Shimose L, Munoz-Price LS. Diagnosis, prevention, and treatment of scabies. Curr Infect Dis Rep. 2013;15(5):426–31.

    Article  PubMed  Google Scholar 

  12. Dourmishev A, Serafimova D, Dourmishev L. Efficacy and tolerance of oral ivermectin in scabies. J Eur Acad Dermatol Venereol. 1998;11(3):247–51.

    Article  CAS  PubMed  Google Scholar 

  13. Chhaiya SB, Patel VJ, Dave JN, Mehta DS, Shah HA. Comparative efficacy and safety of topical permethrin, topical ivermectin, and oral ivermectin in patients of uncomplicated scabies. Indian J Dermatol Venereol Leprol. 2012;78(5):605–10.

    Article  PubMed  Google Scholar 

  14. Goldust M, Rezaee E, Raghifar R, Hemayat S. Comparing the efficacy of oral ivermectin vs malathion 0.5% lotion for the treatment of scabies. Skinmed. 2014;12(5):284–7.

    PubMed  Google Scholar 

  15. Schultz MW, Gomez M, Hansen RC, et al. Comparative study of 5% permethrin cream and 1% lindane lotion for the treatment of scabies. Arch Dermatol. 1990;126(2):167–70.

    Article  CAS  PubMed  Google Scholar 

  16. Goldust M, Babae Nejad S, Rezaee E, Raghifar R. Comparative trial of permethrin 5% versus lindane 1% for the treatment of scabies. J Dermatolog Treat. 2013;

    Google Scholar 

  17. Zargari O, Golchai J, Sobhani A, et al. Comparison of the efficacy of topical 1% lindane vs 5% permethrin in scabies: a randomized, double-blind study. Indian J Dermatol Venereol Leprol. 2006;72(1):33–6.

    Article  PubMed  Google Scholar 

  18. Bachewar NP, Thawani VR, Mali SN, Gharpure KJ, Shingade VP, Dakhale GN. Comparison of safety, efficacy, and cost effectiveness of benzyl benzoate, permethrin, and ivermectin in patients of scabies. Indian J Pharmacol. 2009;41(1):9–14.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Heukelbach J, Feldmeier H. Scabies. Lancet. 2006;367(9524):1767–74.

    Article  PubMed  Google Scholar 

  20. Fujimoto K, Kawasaki Y, Morimoto K, Kikuchi I, Kawana S. Treatment for crusted scabies: limitations and side effects of treatment with ivermectin. J Nippon Med Sch. 2014;81(3):157–63.

    Article  PubMed  Google Scholar 

  21. Chosidow O. Scabies and pediculosis. Lancet. 2000;355(9206):819–26.

    Article  CAS  PubMed  Google Scholar 

  22. Idriss S, Levitt J. Malathion for head lice and scabies: treatment and safety considerations. J Drugs Dermatol. 2009;8(8):715–20.

    PubMed  Google Scholar 

  23. Alipour H, Goldust M. The efficacy of oral ivermectin vs. sulfur 10% ointment for the treatment of scabies. Ann Parasitol. 2015;61(2):79–84.

    PubMed  Google Scholar 

  24. Kenawi MZ, Morsy TA, Abdalla KF, el Hady HM. Treatment of human scabies by sulfur and permethrin. J Egypt Soc Parasitol. 1993;23(3):691–6.

    CAS  PubMed  Google Scholar 

  25. Sharquie KE, Al-Rawi JR, Noaimi AA, Al-Hassany HM. Treatment of scabies using 8% and 10% topical sulfur ointment in different regimens of application. J Drugs Dermatol. 2012;11(3):357–64.

    CAS  PubMed  Google Scholar 

  26. Sule HM, Thacher TD. Comparison of ivermectin and benzyl benzoate lotion for scabies in Nigerian patients. Am J Trop Med Hyg. 2007;76(2):392–5.

    CAS  PubMed  Google Scholar 

  27. Buffet M, Dupin N. Current treatments for scabies. Fundam Clin Pharmacol. 2003;17(2):217–25.

    Article  CAS  PubMed  Google Scholar 

  28. Berthe-Aucejo A, Prot-Labarthe S, Pull L, et al. Treatment of scabies and Ascabiol(®) supply disruption: what about the pediatric population? Arch Pediatr. 2014;21(6):670–5.

    Article  CAS  PubMed  Google Scholar 

  29. Hepburn NC. Cutaneous leishmaniasis: an overview. J Postgrad Med. 2003;49(1):50–4.

    Article  CAS  PubMed  Google Scholar 

  30. Goto H, Lindoso JA. Current diagnosis and treatment of cutaneous and mucocutaneous leishmaniasis. Expert Rev Anti-Infect Ther. 2010;8(4):419–33.

    Article  PubMed  Google Scholar 

  31. Amato VS, Rabello A, Rotondo-Silva A, et al. Successful treatment of cutaneous leishmaniasis with lipid formulations of amphotericin B in two immunocompromised patients. Acta Trop. 2004;92(2):127–32.

    Article  CAS  PubMed  Google Scholar 

  32. Wortmann G, Zapor M, Ressner R, et al. Lipsosomal amphotericin B for treatment of cutaneous leishmaniasis. Am J Trop Med Hyg. 2010;83(5):1028–33.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Dorlo TP, Balasegaram M, Beijnen JH, de Vries PJ. Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis. J Antimicrob Chemother. 2012;67(11):2576–97.

    Article  CAS  PubMed  Google Scholar 

  34. Emad M, Hayati F, Fallahzadeh MK, Namazi MR. Superior efficacy of oral fluconazole 400 mg daily versus oral fluconazole 200 mg daily in the treatment of cutaneous leishmania major infection: a randomized clinical trial. J Am Acad Dermatol. 2011;64(3):606–8.

    Article  CAS  PubMed  Google Scholar 

  35. Alrajhi AA, Ibrahim EA, De Vol EB, Khairat M, Faris RM, Maguire JH. Fluconazole for the treatment of cutaneous leishmaniasis caused by Leishmania major. N Engl J Med. 2002;346(12):891–5.

    Article  CAS  PubMed  Google Scholar 

  36. Khorvash F, Naeini AE, Behjati M, Abdi F. Visceral leishmaniasis in a patient with cutaneous lesions, negative Leishman-Donovan bodies and immunological test: A case report. J Res Med Sci. 2011;16(11):1507–10.

    PubMed  PubMed Central  Google Scholar 

  37. Zijlstra EE, Musa AM, Khalil EA, el-Hassan IM, el-Hassan AM. Post-kala-azar dermal leishmaniasis. Lancet Infect Dis. 2003;3(2):87–98.

    Article  CAS  PubMed  Google Scholar 

  38. Moore EM, Lockwood DN. Treatment of visceral leishmaniasis. J Glob Infect Dis. 2010;2(2):151–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Freitas-Junior LH, Chatelain E, Kim HA, Siqueira-Neto JL. Visceral leishmaniasis treatment: what do we have, what do we need and how to deliver it? Int J Parasitol Drugs Drug Resist. 2012;2:11–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Seifert K, Croft SL. In vitro and in vivo interactions between miltefosine and other antileishmanial drugs. Antimicrob Agents Chemother. 2006;50(1):73–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Belizario V, Delos Trinos JP, Garcia NB, Reyes M. Cutaneous manifestations of selected parasitic infections in Western Pacific and Southeast Asian Regions. Curr Infect Dis Rep. 2016;18(9):30.

    Article  PubMed  Google Scholar 

  42. Gee SN, Rothschild B, Click J, Sheth V, Saavedra A, Hsu MY. Tender ulceronecrotic nodules in a patient with leukemia. Cutaneous acanthamebiasis. Arch Dermatol. 2011;147(7):857–62.

    Article  PubMed  Google Scholar 

  43. Fernández-Antón Martínez MC, Alfageme Roldán F, Ciudad Blanco C, Suárez Fernández R. Ustekinumab in the treatment of severe atopic dermatitis: a preliminary report of our experience with 4 patients. Actas Dermosifiliogr. 2014;105(3):312–3.

    Article  PubMed  Google Scholar 

  44. Morán P, Rojas L, Cerritos R, et al. Case report: cutaneous amebiasis: the importance of molecular diagnosis of an emerging parasitic disease. Am J Trop Med Hyg. 2013;88(1):186–90.

    Article  PubMed  PubMed Central  Google Scholar 

  45. Stanley SL. Amoebiasis. Lancet. 2003;361(9362):1025–34.

    Article  CAS  PubMed  Google Scholar 

  46. Kimura M, Nakamura T, Nawa Y. Experience with intravenous metronidazole to treat moderate-to-severe amebiasis in Japan. Am J Trop Med Hyg. 2007;77(2):381–5.

    CAS  PubMed  Google Scholar 

  47. Lupi O, Bartlett BL, Haugen RN, et al. Tropical dermatology: tropical diseases caused by protozoa. J Am Acad Dermatol. 2009;60(6):897–925. quiz 926-898

    Article  PubMed  Google Scholar 

  48. Swami B, Lavakusulu D, Devi CS. Tinidazole and metronidazole in the treatment of intestinal amoebiasis. Curr Med Res Opin. 1977;5(2):152–6.

    Article  CAS  PubMed  Google Scholar 

  49. Sra KK, Sracic J, Tyring SK. Treatment of protozoan infections. Dermatol Ther. 2004;17(6):513–6.

    Article  PubMed  Google Scholar 

  50. Rossignol JF, Kabil SM, El-Gohary Y, Younis AM. Nitazoxanide in the treatment of amoebiasis. Trans R Soc Trop Med Hyg. 2007;101(10):1025–31.

    Article  CAS  PubMed  Google Scholar 

  51. Parshad S, Grover PS, Sharma A, Verma DK. Primary cutaneous amoebiasis: case report with review of the literature. Int J Dermatol. 2002;41(10):676–80.

    Article  PubMed  Google Scholar 

  52. Ortiz JJ, Ayoub A, Gargala G, Chegne NL, Favennec L. Randomized clinical study of nitazoxanide compared to metronidazole in the treatment of symptomatic giardiasis in children from Northern Peru. Aliment Pharmacol Ther. 2001;15(9):1409–15.

    Article  CAS  PubMed  Google Scholar 

  53. Cabello-Vílchez AM, Rodríguez-Zaragoza S, Piñero J, Valladares B, Lorenzo-Morales J. Balamuthia mandrillaris in South America: an emerging potential hidden pathogen in Perú. Exp Parasitol. 2014;145(Suppl):S10–9.

    Article  PubMed  Google Scholar 

  54. Bravo FG, Alvarez PJ, Gotuzzo E. Balamuthia mandrillaris infection of the skin and central nervous system: an emerging disease of concern to many specialties in medicine. Curr Opin Infect Dis. 2011;24(2):112–7.

    Article  PubMed  Google Scholar 

  55. Moriarty P, Burke C, McCrossin D, et al. Balamuthia mandrillaris encephalitis: survival of a child with severe meningoencephalitis and review of the literature. J Pediatric Infect Dis Soc. 2014;3(1):e4–9.

    Article  PubMed  Google Scholar 

  56. Morrison AO, Morris R, Shannon A, Lauer SR, Guarner J, Kraft CS. Disseminated acanthamoeba infection presenting with cutaneous lesions in an immunocompromised patient: a case report, review of histomorphologic findings, and potential diagnostic pitfalls. Am J Clin Pathol. 2016;145(2):266–70.

    Article  PubMed  Google Scholar 

  57. Galarza C, Ramos W, Gutierrez EL, et al. Cutaneous acanthamebiasis infection in immunocompetent and immunocompromised patients. Int J Dermatol. 2009;48(12):1324–9.

    Article  PubMed  Google Scholar 

  58. Walia R, Montoya JG, Visvesvera GS, Booton GC, Doyle RL. A case of successful treatment of cutaneous Acanthamoeba infection in a lung transplant recipient. Transpl Infect Dis. 2007;9(1):51–4.

    Article  CAS  PubMed  Google Scholar 

  59. Slater CA, Sickel JZ, Visvesvara GS, Pabico RC, Gaspari AA. Brief report: successful treatment of disseminated acanthamoeba infection in an immunocompromised patient. N Engl J Med. 1994;331(2):85–7.

    Article  CAS  PubMed  Google Scholar 

  60. Aichelburg AC, Walochnik J, Assadian O, et al. Successful treatment of disseminated Acanthamoeba sp. infection with miltefosine. Emerg Infect Dis. 2008;14(11):1743–6.

    Article  PubMed  PubMed Central  Google Scholar 

  61. Helton J, Loveless M, White CR. Cutaneous acanthamoeba infection associated with leukocytoclastic vasculitis in an AIDS patient. Am J Dermatopathol. 1993;15(2):146–9.

    Article  CAS  PubMed  Google Scholar 

  62. Seijo Martinez M, Gonzalez-Mediero G, Santiago P, et al. Granulomatous amebic encephalitis in a patient with AIDS: isolation of acanthamoeba sp. Group II from brain tissue and successful treatment with sulfadiazine and fluconazole. J Clin Microbiol. 2000;38(10):3892–5.

    CAS  PubMed  PubMed Central  Google Scholar 

  63. Chaudhry AZ, Longworth DL. Cutaneous manifestations of intestinal helminthic infections. Dermatol Clin. 1989;7(2):275–90.

    CAS  PubMed  Google Scholar 

  64. Keiser J, Utzinger J. Efficacy of current drugs against soil-transmitted helminth infections: systematic review and meta-analysis. JAMA. 2008;299(16):1937–48.

    Article  CAS  PubMed  Google Scholar 

  65. Steinmann P, Utzinger J, ZW D, et al. Efficacy of single-dose and triple-dose albendazole and mebendazole against soil-transmitted helminths and Taenia spp.: a randomized controlled trial. PLoS One. 2011;6(9):e25003.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. de Silva NR, Sirisena JL, Gunasekera DP, Ismail MM, de Silva HJ. Effect of mebendazole therapy during pregnancy on birth outcome. Lancet. 1999;353(9159):1145–9.

    Article  PubMed  Google Scholar 

  67. Cook GC. Enterobius vermicularis infection. Gut. 1994;35(9):1159–62.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  68. Bradley M, Horton J. Assessing the risk of benzimidazole therapy during pregnancy. Trans R Soc Trop Med Hyg. 2001;95(1):72–3.

    Article  CAS  PubMed  Google Scholar 

  69. Feldmeier H, Schuster A. Mini review: Hookworm-related cutaneous larva migrans. Eur J Clin Microbiol Infect Dis. 2012;31(6):915–8.

    Article  CAS  PubMed  Google Scholar 

  70. Caumes E, Carriere J, Datry A, Gaxotte P, Danis M, Gentilini M. A randomized trial of ivermectin versus albendazole for the treatment of cutaneous larva migrans. Am J Trop Med Hyg. 1993;49(5):641–4.

    Article  CAS  PubMed  Google Scholar 

  71. Caumes E. Treatment of cutaneous larva migrans and Toxocara infection. Fundam Clin Pharmacol. 2003;17(2):213–6.

    Article  CAS  PubMed  Google Scholar 

  72. Herman JS, Chiodini PL. Gnathostomiasis, another emerging imported disease. Clin Microbiol Rev. 2009;22(3):484–92.

    Article  PubMed  PubMed Central  Google Scholar 

  73. Rusnak JM, Lucey DR. Clinical gnathostomiasis: case report and review of the English-language literature. Clin Infect Dis. 1993;16(1):33–50.

    Article  CAS  PubMed  Google Scholar 

  74. Nontasut P, Bussaratid V, Chullawichit S, Charoensook N, Visetsuk K. Comparison of ivermectin and albendazole treatment for gnathostomiasis. Southeast Asian J Trop Med Public Health. 2000;31(2):374–7.

    CAS  PubMed  Google Scholar 

  75. Kraivichian K, Nuchprayoon S, Sitichalernchai P, Chaicumpa W, Yentakam S. Treatment of cutaneous gnathostomiasis with ivermectin. Am J Trop Med Hyg. 2004;71(5):623–8.

    CAS  PubMed  Google Scholar 

  76. Lee RM, Moore LB, Bottazzi ME, Hotez PJ. Toxocariasis in North America: a systematic review. PLoS Negl Trop Dis. 2014;8(8):e3116.

    Article  PubMed  PubMed Central  Google Scholar 

  77. Despommier D. Toxocariasis: clinical aspects, epidemiology, medical ecology, and molecular aspects. Clin Microbiol Rev. 2003;16(2):265–72.

    Article  PubMed  PubMed Central  Google Scholar 

  78. Ahn SJ, Ryoo NK, Woo SJ. Ocular toxocariasis: clinical features, diagnosis, treatment, and prevention. Asia Pac Allergy. 2014;4(3):134–41.

    Article  PubMed  PubMed Central  Google Scholar 

  79. Dinning WJ, Gillespie SH, Cooling RJ, Maizels RM. Toxocariasis: a practical approach to management of ocular disease. Eye (Lond). 1988;2(Pt 5):580–2.

    Article  Google Scholar 

  80. Magnaval JF, Glickman LT, Dorchies P, Morassin B. Highlights of human toxocariasis. Korean J Parasitol. 2001;39(1):1–11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  81. Magnaval JF. Comparative efficacy of diethylcarbamazine and mebendazole for the treatment of human toxocariasis. Parasitology. 1995;110(Pt 5):529–33.

    Article  PubMed  Google Scholar 

  82. Lupi O, Downing C, Lee M, et al. Mucocutaneous manifestations of helminth infections: Nematodes. J Am Acad Dermatol. 2015;73(6):929–44. quiz 945-926

    Article  PubMed  Google Scholar 

  83. Kappagoda S, Singh U, Blackburn BG. Antiparasitic therapy. Mayo Clin Proc. 2011;86(6):561–83.

    Article  PubMed  PubMed Central  Google Scholar 

  84. Satoh M, Kokaze A. Treatment strategies in controlling strongyloidiasis. Expert Opin Pharmacother. 2004;5(11):2293–301.

    Article  CAS  PubMed  Google Scholar 

  85. Pungpak S, Bunnag D, Chindanond D, Radmoyos B. Albendazole in the treatment of strongyloidiasis. Southeast Asian J Trop Med Public Health. 1987;18(2):207–10.

    CAS  PubMed  Google Scholar 

  86. Schaffel R, Nucci M, Portugal R, et al. Thiabendazole for the treatment of strongyloidiasis in patients with hematologic malignancies. Clin Infect Dis. 2000;31(3):821–2.

    Article  CAS  PubMed  Google Scholar 

  87. Marti H, Haji HJ, Savioli L, et al. A comparative trial of a single-dose ivermectin versus three days of albendazole for treatment of Strongyloides stercoralis and other soil-transmitted helminth infections in children. Am J Trop Med Hyg. 1996;55(5):477–81.

    Article  CAS  PubMed  Google Scholar 

  88. Henriquez-Camacho C, Gotuzzo E, Echevarria J, et al. Ivermectin versus albendazole or thiabendazole for Strongyloides stercoralis infection. Cochrane Database Syst Rev. 2016;1:CD007745.

    Google Scholar 

  89. Katiyar D, Singh LK. Filariasis: Current status, treatment and recent advances in drug development. Curr Med Chem. 2011;18(14):2174–85.

    Article  CAS  PubMed  Google Scholar 

  90. Reddy M, Gill SS, Kalkar SR, Wu W, Anderson PJ, Rochon PA. Oral drug therapy for multiple neglected tropical diseases: a systematic review. JAMA. 2007;298(16):1911–24.

    Article  CAS  PubMed  Google Scholar 

  91. Haarbrink M, Terhell AJ, Abadi GK, Mitsui Y, Yazdanbakhsh M. Adverse reactions following diethylcarbamazine (DEC) intake in 'endemic normals', microfilaraemics and elephantiasis patients. Trans R Soc Trop Med Hyg. 1999;93(1):91–6.

    Article  CAS  PubMed  Google Scholar 

  92. Moulia-Pelat JP, Nguyen LN, Hascoët H, Luquiaud P, Nicolas L. Advantages of an annual single dose of ivermectin 400 micrograms/kg plus diethylcarbamazine for community treatment of bancroftian filariasis. Trans R Soc Trop Med Hyg. 1995;89(6):682–5.

    Article  CAS  PubMed  Google Scholar 

  93. Hoerauf A, Volkmann L, Hamelmann C, et al. Endosymbiotic bacteria in worms as targets for a novel chemotherapy in filariasis. Lancet. 2000;355(9211):1242–3.

    Article  CAS  PubMed  Google Scholar 

  94. Taylor MJ. Wolbachia bacteria of filarial nematodes in the pathogenesis of disease and as a target for control. Trans R Soc Trop Med Hyg. 2000;94(6):596–8.

    Article  CAS  PubMed  Google Scholar 

  95. Sanprasert V, Sujariyakul A, Nuchprayoon SA. single dose of doxycycline in combination with diethylcarbamazine for treatment of bancroftian filariasis. Southeast Asian J Trop Med Public Health. 2010;41(4):800–12.

    CAS  PubMed  Google Scholar 

  96. Greene BM, Taylor HR, Cupp EW, et al. Comparison of ivermectin and diethylcarbamazine in the treatment of onchocerciasis. N Engl J Med. 1985;313(3):133–8.

    Article  CAS  PubMed  Google Scholar 

  97. Lariviere M, Vingtain P, Aziz M, et al. Double-blind study of ivermectin and diethylcarbamazine in African onchocerciasis patients with ocular involvement. Lancet. 1985;2(8448):174–7.

    Article  CAS  PubMed  Google Scholar 

  98. Simón F, Siles-Lucas M, Morchón R, et al. Human and animal dirofilariasis: the emergence of a zoonotic mosaic. Clin Microbiol Rev. 2012;25(3):507–44.

    Article  PubMed  PubMed Central  Google Scholar 

  99. Jelinek T, Schulte-Hillen J, Löscher T. Human dirofilariasis. Int J Dermatol. 1996;35(12):872–5.

    Article  CAS  PubMed  Google Scholar 

  100. Taylor HR, Greene BM, Langham ME. Controlled clinical trial of oral and topical diethylcarbamazine in treatment of onchocerciasis. Lancet. 1980;1(8175):943–6.

    Article  CAS  PubMed  Google Scholar 

  101. Mota LS, Silva SF, Almeida FC, Mesquita LS, Teixeira RD, Soares AM. Ectopic cutaneous schistosomiasis - case report. An Bras Dermatol. 2014;89(4):646–8.

    Article  PubMed Central  Google Scholar 

  102. Nunes KM, Cardoso AE, Pereira FS, Batista LH, Houly RL. Ectopic cutaneous schistosomiasis—case report. An Bras Dermatol. 2013;88(6):969–72.

    Article  PubMed  PubMed Central  Google Scholar 

  103. Hoeffler DF. Cercarial dermatitis. Arch Environ Health. 1974;29(4):225–9.

    Article  CAS  PubMed  Google Scholar 

  104. Centers for Disease Control (CDC). Cercarial dermatitis outbreak at a state park—Delaware, 1991. MMWR Morb Mortal Wkly Rep. 1992;41(14):225–8.

    Google Scholar 

  105. GY W, Halim MH. Schistosomiasis: progress and problems. World J Gastroenterol. 2000;6(1):12–9.

    Article  Google Scholar 

  106. Wolff K, Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell DJ. Fitzpatrick’s dermatology in general medicine, 2 volumes. Transplantation. 2008; 85(654).

    Google Scholar 

  107. Wortman PD. Subcutaneous cysticercosis. J Am Acad Dermatol. 1991;25(2 Pt 2):409–14.

    Article  CAS  PubMed  Google Scholar 

  108. Schmidt DK, Jordaan HF, Schneider JW, Cilliers J. Cerebral and subcutaneous cysticercosis treated with albendazole. Int J Dermatol. 1995;34(8):574–9.

    Article  CAS  PubMed  Google Scholar 

  109. Kraft R. Cysticercosis: an emerging parasitic disease. Am Fam Physician. 2007;76(1):91–6.

    PubMed  Google Scholar 

  110. Greenaway C. Dracunculiasis (guinea worm disease). CMAJ. 2004;170(4):495–500.

    PubMed  PubMed Central  Google Scholar 

  111. Pardanani DS, Trivedi VD, Joshi LG, Daulatram J, Nandi JS. Metronidazole (“Flagyl”) in dracunculiasis: a double blind study. Ann Trop Med Parasitol. 1977;71(1):45–52.

    Article  CAS  PubMed  Google Scholar 

  112. Magnussen P, Yakubu A, Bloch P. The effect of antibiotic- and hydrocortisone-containing ointments in preventing secondary infections in guinea worm disease. Am J Trop Med Hyg. 1994;51(6):797–9.

    Article  CAS  PubMed  Google Scholar 

  113. Belcher DW, Wunapa FK, Ward WB. Failure of thiabendazole and metronidazole in the treatment and suppression of guinea worm disease. Am J Trop Med Hyg. 1975;24(3):444–6.

    Article  CAS  PubMed  Google Scholar 

  114. Kale OO, Elemile T, Enahoro F. Controlled comparative trial of thiabendazole and metronidazole in the treatment of dracontiasis. Ann Trop Med Parasitol. 1983;77(2):151–7.

    Article  CAS  PubMed  Google Scholar 

  115. Padgett JJ, Jacobsen KH. Loiasis: African eye worm. Trans R Soc Trop Med Hyg. 2008;102(10):983–9.

    Article  PubMed  Google Scholar 

  116. Elgart ML. Onchocerciasis and dracunculosis. Dermatol Clin. 1989;7(2):323–30.

    CAS  PubMed  Google Scholar 

  117. Nutman TB, Miller KD, Mulligan M, et al. Diethylcarbamazine prophylaxis for human loiasis. Results of a double-blind study. N Engl J Med. 1988;319(12):752–6.

    Article  CAS  PubMed  Google Scholar 

  118. Enk CD. Onchocerciasis—river blindness. Clin Dermatol. 2006;24(3):176–80.

    Article  PubMed  Google Scholar 

  119. Aziz MA, Diallo S, Diop IM, Lariviere M, Porta M. Efficacy and tolerance of ivermectin in human onchocerciasis. Lancet. 1982;2(8291):171–3.

    Article  CAS  PubMed  Google Scholar 

  120. Gardon J, Boussinesq M, Kamgno J, Gardon-Wendel N, Demanga-Ngangue DBO. Effects of standard and high doses of ivermectin on adult worms of Onchocerca volvulus: a randomised controlled trial. Lancet. 2002;360(9328):203–10.

    Article  CAS  PubMed  Google Scholar 

  121. Taylor MJ, Hoerauf A, Townson S, Slatko BE, Ward SA. Anti-Wolbachia drug discovery and development: safe macrofilaricides for onchocerciasis and lymphatic filariasis. Parasitology. 2014;141(1):119–27.

    Article  CAS  PubMed  Google Scholar 

  122. Specht S, Mand S, Marfo-Debrekyei Y, et al. Efficacy of 2- and 4-week rifampicin treatment on the Wolbachia of Onchocerca volvulus. Parasitol Res. 2008;103(6):1303–9.

    Article  PubMed  Google Scholar 

  123. Bah GS, Ward EL, Srivastava A, Trees AJ, Tanya VN, Makepeace BL. Efficacy of three-week oxytetracycline or rifampin monotherapy compared with a combination regimen against the filarial nematode Onchocerca ochengi. Antimicrob Agents Chemother. 2014;58(2):801–10.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  124. Hoerauf A. Filariasis: new drugs and new opportunities for lymphatic filariasis and onchocerciasis. Curr Opin Infect Dis. 2008;21(6):673–81.

    Article  CAS  PubMed  Google Scholar 

  125. Wanji S, Tendongfor N, Nji T, et al. Community-directed delivery of doxycycline for the treatment of onchocerciasis in areas of co-endemicity with loiasis in Cameroon. Parasit Vectors. 2009;2(1):39.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  126. Klion AD, Horton J, Nutman TB. Albendazole therapy for loiasis refractory to diethylcarbamazine treatment. Clin Infect Dis. 1999;29(3):680–2.

    Article  CAS  PubMed  Google Scholar 

  127. Moro P, Schantz PM. Echinococcosis: a review. Int J Infect Dis. 2009;13(2):125–33.

    Article  CAS  PubMed  Google Scholar 

  128. Velasco-Tirado V, Yuste-Chaves M, Belhassen-García M. Cutaneous disease as the first manifestation of cystic echinococcosis. Am J Trop Med Hyg. 2016;95(2):257–9.

    Article  PubMed  PubMed Central  Google Scholar 

  129. Bresson-Hadni S, Humbert P, Paintaud G, et al. Skin localization of alveolar echinococcosis of the liver. J Am Acad Dermatol. 1996;34(5 Pt 2):873–7.

    Article  CAS  PubMed  Google Scholar 

  130. Ferré-Ybarz L, Galán CG, Palau AT, de la Borbolla JM, Falcó SN. Recurrent angioedema and urticaria in patient with severe osteoporosis. Allergol Immunopathol (Madr). 2011;39(6):379–80.

    Article  Google Scholar 

  131. Horton RJ. Albendazole in treatment of human cystic echinococcosis: 12 years of experience. Acta Trop. 1997;64(1–2):79–93.

    Article  CAS  PubMed  Google Scholar 

  132. Caldwell JP. Pinworms (enterobius vermicularis). Can Fam Physician. 1982;28:306–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  133. Lormans JA, Wesel AJ, Vanparus OF. Mebendazole (R 17635) in enterobiasis. A clinical trial in mental retardates. Chemotherapy. 1975;21(3–4):255–60.

    Article  CAS  PubMed  Google Scholar 

  134. St Georgiev V. Chemotherapy of enterobiasis (oxyuriasis). Expert Opin Pharmacother. 2001;2(2):267–75.

    Article  CAS  PubMed  Google Scholar 

  135. Ragan JT. Single-dose treatment of enterobiasis-use of a new piperazine-senna preparation. Calif Med. 1962;97(6):338–40.

    CAS  PubMed  PubMed Central  Google Scholar 

  136. Brown HW, Chan KF, Hussey KL. Treatment of enterobiasis and ascariasis with piperazine. J Am Med Assoc. 1956;161(6):515–20.

    Article  CAS  PubMed  Google Scholar 

  137. Rachelson M, Ferguson W. Piperazine in the treatment of enterobiasis. AMA Am J Dis Child. 1955;89:346–9.

    CAS  PubMed  Google Scholar 

  138. White RH, Standen OD. Piperazine in the treatment of threadworms in children; report on a clinical trial. Br Med J. 1953;2(4839):755–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  139. Heukelbach J, Wilcke T, Winter B, et al. Efficacy of ivermectin in a patient population concomitantly infected with intestinal helminths and ectoparasites. Arzneimittelforschung. 2004;54(7):416–21.

    CAS  PubMed  Google Scholar 

  140. Naquira C, Jimenez G, Guerra JG, et al. Ivermectin for human strongyloidiasis and other intestinal helminths. Am J Trop Med Hyg. 1989;40(3):304–9.

    Article  CAS  PubMed  Google Scholar 

  141. Li B, Flaveny CA, Giambelli C, et al. Repurposing the FDA-approved pinworm drug pyrvinium as a novel chemotherapeutic agent for intestinal polyposis. PLoS One. 2014;9(7):e101969.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  142. Desai AS. Single-dose treatment of oxyuriasis with pyrvinium embonate. Br Med J. 1962;2(5319):1583–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  143. Wolfe MS. Oxyuris, trichostrongylus and trichuris. Clin Gastroenterol. 1978;7(1):201–17.

    CAS  PubMed  Google Scholar 

  144. Barua AC, Deka P, Das BN. Clinical trial of piperazine hydrate and pyrvinium pamoate in ascariasis and oxyuriasis infestation. Indian J Pediatr. 1979;46(376):182–6.

    Article  CAS  PubMed  Google Scholar 

  145. Sinnis P, Zavala F. The skin: where malaria infection and the host immune response begin. Semin Immunopathol. 2012;34(6):787–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  146. Vaishnani JB. Cutaneous findings in five cases of malaria. Indian J Dermatol Venereol Leprol. 2011;77(1):110.

    Article  PubMed  Google Scholar 

  147. Nagayasu E, Yoshida A, Hombu A, Horii Y, Maruyama H. Paragonimiasis in Japan: a twelve-year retrospective case review (2001-2012). Intern Med. 2015;54(2):179–86.

    Article  PubMed  Google Scholar 

  148. Sogandares-Bernal F, Seed JR. American paragonimiasis. Curr Top Comp Pathobiol. 1973;2:1–56.

    Article  CAS  PubMed  Google Scholar 

  149. Procop GW. North American paragonimiasis (Caused by Paragonimus kellicotti) in the context of global paragonimiasis. Clin Microbiol Rev. 2009;22(3):415–46.

    Article  PubMed  PubMed Central  Google Scholar 

  150. Saborio P, Lanzas R, Arrieta G, Arguedas A. Paragonimus mexicanus pericarditis: report of two cases and review of the literature. J Trop Med Hyg. 1995;98(5):316–8.

    CAS  PubMed  Google Scholar 

  151. Johnson RJ, Jong EC, Dunning SB, Carberry WL, Minshew BH. Paragonimiasis: diagnosis and the use of praziquantel in treatment. Rev Infect Dis. 1985;7(2):200–6.

    Article  CAS  PubMed  Google Scholar 

  152. Udonsi JK. Clinical field trials of praziquantel in pulmonary paragonimiasis due to Paragonimus uterobilateralis in endemic populations of the Igwun Basin, Nigeria. Trop Med Parasitol. 1989;40(1):65–8.

    CAS  PubMed  Google Scholar 

  153. Calvopiña M, Guderian RH, Paredes W, Chico M, Cooper PJ. Treatment of human pulmonary paragonimiasis with triclabendazole: clinical tolerance and drug efficacy. Trans R Soc Trop Med Hyg. 1998;92(5):566–9.

    Article  PubMed  Google Scholar 

  154. Villegas F, Angles R, Barrientos R, et al. Administration of triclabendazole is safe and effective in controlling fascioliasis in an endemic community of the Bolivian Altiplano. PLoS Negl Trop Dis. 2012;6(8):e1720.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  155. Johnson G, Gardner J, Fukai T, Goto K. Cutaneous sparganosis: a rare parasitic infection. J Cutan Pathol. 2015;42(1):1–5.

    Article  PubMed  Google Scholar 

  156. Griffin MP, Tompkins KJ, Ryan MT. Cutaneous sparganosis. Am J Dermatopathol. 1996;18(1):70–2.

    Article  CAS  PubMed  Google Scholar 

  157. Fischer P, Bamuhiiga J, Büttner DW. Treatment of human Mansonella streptocerca infection with ivermectin. Tropical Med Int Health. 1997;2(2):191–9.

    Article  CAS  Google Scholar 

  158. Meyers WM, Moris R, Neafie RC, Connor DH, Bourland J. Streptocerciasis: degeneration of adult Dipetalonema streptocerca in man following diethylcarbamazine therapy. Am J Trop Med Hyg. 1978;27(6):1137–47.

    Article  CAS  PubMed  Google Scholar 

  159. Awadzi K, Gilles HM. Diethylcarbamazine in the treatment of patients with onchocerciasis. Br J Clin Pharmacol. 1992;34(4):281–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  160. Saadatnia G, Golkar M. A review on human toxoplasmosis. Scand J Infect Dis. 2012;44(11):805–14.

    Article  PubMed  Google Scholar 

  161. Beverley JK. Congenital toxoplasma infections. Proc R Soc Med. 1960;53:111–3.

    CAS  PubMed  Google Scholar 

  162. Mawhorter SD, Effron D, Blinkhorn R, Spagnuolo PJ. Cutaneous manifestations of toxoplasmosis. Clin Infect Dis. 1992;14(5):1084–8.

    Article  CAS  PubMed  Google Scholar 

  163. Leyva WH, Santa Cruz DJ. Cutaneous toxoplasmosis. J Am Acad Dermatol. 1986;14(4):600–5.

    Article  CAS  PubMed  Google Scholar 

  164. Rajapakse S, Chrishan Shivanthan M, Samaranayake N, Rodrigo C, Deepika Fernando S. Antibiotics for human toxoplasmosis: a systematic review of randomized trials. Pathog Glob Health. 2013;107(4):162–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  165. Gottstein B, Pozio E, Nöckler K. Epidemiology, diagnosis, treatment, and control of trichinellosis. Clin Microbiol Rev. 2009;22(1):127–45. Table of Contents

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  166. Cabié A, Bouchaud O, Houzé S, et al. Albendazole versus thiabendazole as therapy for trichinosis: a retrospective study. Clin Infect Dis. 1996;22(6):1033–5.

    Article  PubMed  Google Scholar 

  167. Kissinger P. Trichomonas vaginalis: a review of epidemiologic, clinical and treatment issues. BMC Infect Dis. 2015;15:307.

    Article  PubMed  PubMed Central  Google Scholar 

  168. Lossick JG. Treatment of trichomonas vaginalis infections. Rev Infect Dis. 1982;4:S801–18.

    Google Scholar 

  169. Cudmore SL, Garber GE. Prevention or treatment: the benefits of Trichomonas vaginalis vaccine. J Infect Public Health. 2010;3(2):47–53.

    Article  PubMed  Google Scholar 

  170. Thulkar J, Kriplani A, Agarwal N. A comparative study of oral single dose of metronidazole, tinidazole, secnidazole and ornidazole in bacterial vaginosis. Indian J Pharmacol. 2012;44(2):243–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  171. Schwebke JR, Desmond RA. Tinidazole vs metronidazole for the treatment of bacterial vaginosis. Am J Obstet Gynecol. 2011;204(3):211.e211–6.

    Article  CAS  Google Scholar 

  172. McGovern TW, Williams W, Fitzpatrick JE, Cetron MS, Hepburn BC, Gentry RH. Cutaneous manifestations of African trypanosomiasis. Arch Dermatol. 1995;131(10):1178–82.

    Article  CAS  PubMed  Google Scholar 

  173. Scott JA, Davidson RN, Moody AH, Bryceson AD. Diagnosing multiple parasitic infections: trypanosomiasis, loiasis and schistosomiasis in a single case. Scand J Infect Dis. 1991;23(6):777–80.

    Article  CAS  PubMed  Google Scholar 

  174. Babokhov P, Sanyaolu AO, Oyibo WA, Fagbenro-Beyioku AF, Iriemenam NC. A current analysis of chemotherapy strategies for the treatment of human African trypanosomiasis. Pathog Glob Health. 2013;107(5):242–52.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  175. Pépin J, Milord F, Meurice F, Ethier L, Loko L, Mpia B. High-dose nifurtimox for arseno-resistant Trypanosoma brucei gambiense sleeping sickness: an open trial in central Zaire. Trans R Soc Trop Med Hyg. 1992;86(3):254–6.

    Article  PubMed  Google Scholar 

  176. Pepin J, Milord F, Mpia B, et al. An open clinical trial of nifurtimox for arseno-resistant Trypanosoma brucei gambiense sleeping sickness in central Zaire. Trans R Soc Trop Med Hyg. 1989;83(4):514–7.

    Article  CAS  PubMed  Google Scholar 

  177. Priotto G, Kasparian S, Mutombo W, et al. Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial. Lancet. 2009;374(9683):56–64.

    Article  CAS  PubMed  Google Scholar 

  178. Bisser S, N'Siesi FX, Lejon V, et al. Equivalence trial of melarsoprol and nifurtimox monotherapy and combination therapy for the treatment of second-stage Trypanosoma brucei gambiense sleeping sickness. J Infect Dis. 2007;195(3):322–9.

    Article  CAS  PubMed  Google Scholar 

  179. Hemmige V, Tanowitz H, Sethi A. Trypanosoma cruzi infection: a review with emphasis on cutaneous manifestations. Int J Dermatol. 2012;51(5):501–8.

    Article  PubMed  PubMed Central  Google Scholar 

  180. Sparsa A, Bonnetblanc JM, Peyrot I, Loustaud-Ratti V, Vidal E, Bédane C. Systemic adverse reactions with ivermectin treatment of scabies. Ann Dermatol Venereol. 2006;133(10):784–7.

    Article  CAS  PubMed  Google Scholar 

  181. Veit O, Beck B, Steuerwald M, Hatz C. First case of ivermectin-induced severe hepatitis. Trans R Soc Trop Med Hyg. 2006;100(8):795–7.

    Article  PubMed  Google Scholar 

  182. Sudakin DL. Fatality after a single dermal application of lindane lotion. Arch Environ Occup Health. 2007;62(4):201–3.

    Article  PubMed  Google Scholar 

  183. Schimmel M, Abrahamov A, Brama I. A rare complication of aplastic anemia due to Lindane intoxication. Harefuah. 1980;98(8):355–6.

    CAS  PubMed  Google Scholar 

  184. Brahams D. Lindane exposure and aplastic anaemia. Lancet. 1994;343(8905):1092.

    Article  CAS  PubMed  Google Scholar 

  185. Rauch AE, Kowalsky SF, Lesar TS, Sauerbier GA, Burkart PT, Scharfman WB. Lindane (Kwell)-induced aplastic anemia. Arch Intern Med. 1990;150(11):2393–5.

    Article  CAS  PubMed  Google Scholar 

  186. Morgan DP, Roberts RJ, Walter AW, Stockdale EM. Anemia associated with exposure to lindane. Arch Environ Health. 1980;35(5):307–10.

    Article  CAS  PubMed  Google Scholar 

  187. Loge JP. Aplastic anemia following exposure to benzene hexachloride (Lindane). JAMA. 1965;193:110–4.

    Article  CAS  PubMed  Google Scholar 

  188. Albahary C, Dubrisay J, Guerin H. Obstinate pancytopenia due to lindane (gamma isomer of hexachlorocyclohexane). Arch Mal Prof. 1957;18(6):687–91.

    CAS  PubMed  Google Scholar 

  189. Burgess I. Adverse reactions to monosulfiram. Lancet. 1990;336(8719):873.

    Article  CAS  PubMed  Google Scholar 

  190. Gursale S, Chargulla S, Khanwelkar C, Thorat V, Gaonkar R, Jadhav S. Metronidazole-Furazolidone induced Stevens-Johnson Syndrome. Indian Medical Gazette. 2010.

    Google Scholar 

  191. Piskin G, Mekkes J. Stevens-Johnson syndrome from metronidazole. Contact Dermatitis. 2006;55:192–3.

    Article  CAS  PubMed  Google Scholar 

  192. Egan CA, Grant WJ, Morris SE, Saffle JR, Zone JJ. Plasmapheresis as an adjunct treatment in toxic epidermal necrolysis. J Am Acad Dermatol. 1999;40(3):458–61.

    Article  CAS  PubMed  Google Scholar 

  193. Magazine R, Chogtu B. Stevens Johnson syndrome and neurotoxic effects of metronidazole. Indian J Pharmacol. 2014;46(5):565.

    PubMed  PubMed Central  Google Scholar 

  194. Mazumdar G, Shome K. Stevens-Johnson syndrome following use of metronidazole in a dental patient. Indian J Pharmacol. 2014;46(1):121–2.

    Article  PubMed  PubMed Central  Google Scholar 

  195. Chen KT, Twu SJ, Chang HJ, Lin RS. Outbreak of Stevens-Johnson syndrome/toxic epidermal necrolysis associated with mebendazole and metronidazole use among Filipino laborers in Taiwan. Am J Public Health. 2003;93(3):489–92.

    Article  PubMed  PubMed Central  Google Scholar 

  196. Hobbs K, Stern-Nezer S, Buckwalter MS, Fischbein N, Finley Caulfield A. Metronidazole-induced encephalopathy: not always a reversible situation. Neurocrit Care. 2015;22(3):429–36.

    Article  PubMed  Google Scholar 

  197. Bahn Y, Kim E, Park C, Park HC. Metronidazole induced encephalopathy in a patient with brain abscess. J Korean Neurosurg Soc. 2010;48(3):301–4.

    Article  PubMed  PubMed Central  Google Scholar 

  198. Huang YT, Chen LA, Cheng SJ. Metronidazole-induced encephalopathy: case report and review literature. Acta Neurol Taiwanica. 2012;21(2):74–8.

    Google Scholar 

  199. Cheong HC, Jeong TG, Cho YB, et al. Metronidazole-induced encephalopathy in a patient with liver cirrhosis. Korean J Hepatol. 2011;17(2):157–60.

    Article  PubMed  PubMed Central  Google Scholar 

  200. Thakkar N, Bhaarat S, Chand R, et al. Metronidazole induced encephalopathy. J Assoc Physicians India. 2016;64(11):72–4.

    PubMed  Google Scholar 

  201. Jang HJ, Sim SY, Lee JY, Bang JH. Atypical metronidazole-induced encephalopathy in anaerobic brain abscess. J Korean Neurosurg Soc. 2012;52(3):273–6.

    Article  PubMed  PubMed Central  Google Scholar 

  202. Arik N, Cengiz N, Bilge A. Metronidazole-induced encephalopathy in a uremic patient: a case report. Nephron. 2001;89(1):108–9.

    Article  CAS  PubMed  Google Scholar 

  203. Kim H, Kim YW, Kim SR, Park IS, Jo KW. Metronidazole-induced encephalopathy in a patient with infectious colitis: a case report. J Med Case Rep. 2011;5:63.

    Article  PubMed  PubMed Central  Google Scholar 

  204. Seok JI, Yi H, Song YM, Lee WY. Metronidazole-induced encephalopathy and inferior olivary hypertrophy: lesion analysis with diffusion-weighted imaging and apparent diffusion coefficient maps. Arch Neurol. 2003;60(12):1796–800.

    Article  PubMed  Google Scholar 

  205. Papathanasiou A, Zouvelou V, Kyriazi S, Rentzos M, Evdokimidis I. Metronidazole-induced reversible encephalopathy in a patient with facioscapulohumeral muscular dystrophy. Clin Neuroradiol. 2013;23(3):217–9.

    Article  PubMed  Google Scholar 

  206. Yagi T, Shihashi G, Oki K, et al. Metronidazole-induced encephalopathy and myoclonus: case report and a review of the literature. Neurol Clin Neurosci. 2015;3:111–3.

    Article  Google Scholar 

  207. Onder H, et al. J Neurol Res. 2016;6(4):81–4.

    Article  Google Scholar 

  208. Haridas A, Trivedi TH, Moulick ND, Joshi AR. Metronidazole-induced encephalopathy in chronic diarrhoea. J Assoc Physicians India. 2015;63(6):77–9.

    PubMed  Google Scholar 

  209. Godfrey MS, Finn A, Zainah H, Dapaah-Afriyie K. Metronidazole-induced encephalopathy after prolonged metronidazole course for treatment of C. difficile colitis. BMJ Case Rep. 2015;2015:bcr2014206162.

    Article  PubMed  PubMed Central  Google Scholar 

  210. Furukawa S, Yamamoto T, Sugiyama A, et al. Metronidazole-induced encephalopathy with contrast enhancing lesions on MRI. J Neurol Sci. 2015;352(1–2):129–31.

    Article  PubMed  Google Scholar 

  211. Kalia V, Vibhuti SK. Case report: MRI of the brain in metronidazole toxicity. Indian J Radiol Imaging. 2010;20(3):195–7.

    Article  PubMed  PubMed Central  Google Scholar 

  212. Corson AP, Chretien JH. Metronidazole-associated aseptic meningitis. Clin Infect Dis. 1994;19(5):974.

    Article  CAS  PubMed  Google Scholar 

  213. Khan S, Sharrack B, Sewell WA. Metronidazole-induced aseptic meningitis during Helicobacter pylori eradication therapy. Ann Intern Med. 2007;146(5):395–6.

    Article  PubMed  Google Scholar 

  214. Hari A, Srikanth BA, Lakshmi GS. Metronidazole induced cerebellar ataxia. Indian J Pharmacol. 2013;45(3):295–7.

    Article  PubMed  PubMed Central  Google Scholar 

  215. Kuriyama A, Jackson JL, Doi A, Kamiya T. Metronidazole-induced central nervous system toxicity: a systematic review. Clin Neuropharmacol. 2011;34(6):241–7.

    Article  CAS  PubMed  Google Scholar 

  216. Ogundipe OA. Metronidazole associated seizures: a case report and review of the pharmacovigilance literature. Int J Basic Clin Pharmacol. 2014;3(1):235–8.

    Article  Google Scholar 

  217. Smith JA. Neutropenia associated with metronidazole therapy. Can Med Assoc J. 1980;123(3):202.

    CAS  PubMed  PubMed Central  Google Scholar 

  218. Sanders CV, Hanna BJ, Lewis AC. Metronidazole in the treatment of anaerobic infections. Am Rev Respir Dis. 1979;120(2):337–43.

    CAS  PubMed  Google Scholar 

  219. Taylor JA. Metronidazole and transient leukopenia. JAMA. 1965;194(12):1331–2.

    Article  CAS  PubMed  Google Scholar 

  220. Choi GY, Yang HW, Cho SH, et al. Acute drug-induced hepatitis caused by albendazole. J Korean Med Sci. 2008;23(5):903–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  221. Marin Zuluaga JI, Marin Castro AE, Perez Cadavid JC, Restrepo Gutierrez JC. Albendazole-induced granulomatous hepatitis: a case report. J Med Case Rep. 2013;7:201.

    Article  PubMed  PubMed Central  Google Scholar 

  222. Ben Fredj N, Chaabane A, Chadly Z, Ben Fadhel N, Boughattas NA, Aouam K. Albendazole-induced associated acute hepatitis and bicytopenia. Scand J Infect Dis. 2014;46(2):149–51.

    Article  PubMed  Google Scholar 

  223. Amoruso C, Fuoti M, Miceli V, et al. Acute hepatitis as a side effect of albendazole: a pediatric case. Pediatr Med Chir. 2009;31(4):176–8.

    PubMed  Google Scholar 

  224. Shah C, Mahapatra A, Shukla A, Bhatia S. Recurrent acute hepatitis caused by albendazole. Trop Gastroenterol. 2013;34(1):38–9.

    Article  PubMed  Google Scholar 

  225. Gözüküçük R, Abci İ, Güçlü M. Albendazole-induced toxic hepatitis: a case report. Turk J Gastroenterol. 2013;24(1):82–4.

    Article  PubMed  Google Scholar 

  226. Ríos D, Restrepo JC. Albendazole-induced liver injury: a case report. Colomb Med (Cali). 2013;44(2):118–20.

    Google Scholar 

  227. Sharma R, Mathur MN. Stevens-Johnson syndrome following sulfadiazine, Tri-sulfose and sulfatriad therapy. J Assoc Physicians India. 1965;13(9):727–30.

    CAS  PubMed  Google Scholar 

  228. Dewerdt S, Machet L, Jan-Lamy V, Lorette G, Therizol-Ferly M, Vaillant L. Stevens-Johnson syndrome after albendazole. Acta Derm Venereol. 1997;77(5):411.

    CAS  PubMed  Google Scholar 

  229. Batzlaff CM, Pupaibool J, Sohail MR. Acute renal failure associated with albendazole therapy in a patient with trichinosis. BMJ Case Rep. 2014;2014:bcr2013200668.

    Article  PubMed  PubMed Central  Google Scholar 

  230. Opatrny L, Prichard R, Snell L, Maclean JD. Death related to albendazole-induced pancytopenia: case report and review. Am J Trop Med Hyg. 2005;72(3):291–4.

    PubMed  Google Scholar 

  231. Wilmshurst JM, Robb SA. Can mebendazole cause lateralized occipital seizures? Eur J Paediatr Neurol. 1998;2(6):323–4.

    Article  CAS  PubMed  Google Scholar 

  232. Levin MH, Weinstein RA, Axelrod JL, Schantz PM. Severe, reversible neutropenia during high-dose mebendazole therapy for echinococcosis. JAMA. 1983;249(21):2929–31.

    Article  CAS  PubMed  Google Scholar 

  233. Kammerer WS, Schantz PM. Long term follow-up of human hydatid disease (Echinococcus granulosus) treated with a high-dose mebendazole regimen. Am J Trop Med Hyg. 1984;33(1):132–7.

    Article  CAS  PubMed  Google Scholar 

  234. Junge U, Mohr W. Mebendazole-hepatitis. Z Gastroenterol. 1983;21(12):736–8.

    CAS  PubMed  Google Scholar 

  235. Colle I, Naegels S, Hoorens A, Hautekeete M. Granulomatous hepatitis due to mebendazole. J Clin Gastroenterol. 1999;28(1):44–5.

    Article  CAS  PubMed  Google Scholar 

  236. Shcherbakov AM, Kozlova TL, Bebris NK. Agranulocytosis–a complication of the chemotherapy of echinococcosis with mebendazole. Med Parazitol (Mosk). 1992;(5-6):9–11.

    Google Scholar 

  237. Fernández-Bañares F, González-Huix F, Xiol X, et al. Marrow aplasia during high dose mebendazole treatment. Am J Trop Med Hyg. 1986;35(2):350–1.

    Article  PubMed  Google Scholar 

  238. Ashubu OF, Ademola AD, Asinobi AO. A case report of suspected angioedema in a child after administration of mebendazole, cotrimoxazole and leaf extracts. Ann Ib Postgrad Med. 2016;14(1):41–3.

    CAS  PubMed  PubMed Central  Google Scholar 

  239. Tchao P, Templeton T. Thiabendazole-associated grand mal seizures in a patient with Down syndrome. J Pediatr. 1983;102(2):317–8.

    Article  CAS  PubMed  Google Scholar 

  240. Robinson HM, Samorodin CS. Thiabendazole-induced toxic epidermal necrolysis. Arch Dermatol. 1976;112(12):1757–60.

    Article  CAS  PubMed  Google Scholar 

  241. Johnson-Reagan L, Bahna SL. Severe drug rashes in three siblings simultaneously. Allergy. 2003;58(5):445–7.

    Article  CAS  PubMed  Google Scholar 

  242. Eland IA, Kerkhof SC, Overbosch D, Wismans PJ, Stricker BH. Cholestatic hepatitis ascribed to the use of thiabendazole. Ned Tijdschr Geneeskd. 1998;142(23):1331–4.

    CAS  PubMed  Google Scholar 

  243. Ambroise-Thomas P, Meyer HA. Hepatic amebiasis in the Kilimanjaro region. Serodiagnosis on micro-specimens of dried blood and attempts at treatment with tinidazole (fasigyn). Acta Trop. 1975;32(4):359–64.

    CAS  PubMed  Google Scholar 

  244. Tabak F, Ozaras R, Erzin Y, Celik AF, Ozbay G, Senturk H. Ornidazole-induced liver damage: report of three cases and review of the literature. Liver Int. 2003;23(5):351–4.

    Article  PubMed  Google Scholar 

  245. Ersöz G, Vardar R, Akarca US, et al. Ornidazole-induced autoimmune hepatitis. Turk J Gastroenterol. 2011;22(5):494–9.

    Article  PubMed  Google Scholar 

  246. Harputluoglu MM, Demirel U, Karadag N, et al. Severe hepatitis with prolonged cholestasis and bile duct injury due the long-term use of ornidazole. Acta Gastroenterol Belg. 2007;70(3):293–5.

    PubMed  Google Scholar 

  247. Azher M, el-Kassimi FA, Wright SG, Mofti A. Exudative polyserositis and acute respiratory failure following praziquantel therapy. Chest. 1990;98(1):241–3.

    Article  CAS  PubMed  Google Scholar 

  248. Bada JL, Treviño B, Cabezos J. Convulsive seizures after treatment with praziquantel. Br Med J (Clin Res Ed). 1988;296(6622):646.

    Article  CAS  Google Scholar 

  249. Lima AW, Medeiros Z, Santos ZC, Costa GM, Braga C. Adverse reactions following mass drug administration with diethylcarbamazine in lymphatic filariasis endemic areas in the Northeast of Brazil. Rev Soc Bras Med Trop. 2012;45(6):745–50.

    Article  PubMed  Google Scholar 

  250. Carrascosa MF, Lucena MI, Andrade RJ, et al. Fatal acute hepatitis after sequential treatment with levofloxacin, doxycycline, and naproxen in a patient presenting with acute Mycoplasma pneumoniae infection. Clin Ther. 2009;31(5):1014–9.

    Article  PubMed  Google Scholar 

  251. Selimoglu MA, Ertekin V. Autoimmune hepatitis triggered by Brucella infection or doxycycline or both. Int J Clin Pract. 2003;57(7):639–41.

    CAS  PubMed  Google Scholar 

  252. Perlmutter A, Abramovits W, Gupta AK. Oracea (doxycycline monohydrate). Skinmed. 2006;5(5):238–40.

    Article  PubMed  Google Scholar 

  253. Takahashi R, Tsukada T, Hasegawa M. Tetracycline-induced hemolytic anemia. Keio J Med. 1963;12:161–8.

    Article  CAS  PubMed  Google Scholar 

  254. Tabibian JH, Gutierrez MA. Doxycycline-induced pseudotumor cerebri. South Med J. 2009;102(3):310–1.

    Article  PubMed  Google Scholar 

  255. Lochhead J, Elston JS. Doxycycline induced intracranial hypertension. BMJ. 2003;326(7390):641–2.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  256. Friedman SJ, Winkelmann RK. Familial granuloma annulare. Report of two cases and review of the literature. J Am Acad Dermatol. 1987;16(3 Pt 1):600–5.

    Article  CAS  PubMed  Google Scholar 

  257. Kadam P, Gregory NA, Zelger B, Carlson JA. Delayed onset of the Jarisch-Herxheimer reaction in doxycycline-treated disease: a case report and review of its histopathology and implications for pathogenesis. Am J Dermatopathol. 2015;37(6):e68–74.

    Article  PubMed  Google Scholar 

  258. Haney C, Nahata MC. Unique expression of chronic Lyme disease and Jarisch-Herxheimer reaction to doxycycline therapy in a young adult. BMJ Case Rep. 2016;2016:bcr2013009433.

    Article  PubMed  Google Scholar 

  259. Kadayifci A, Gulsen MT, Koruk M, Savas MC. Doxycycline-induced pill esophagitis. Dis Esophagus. 2004;17(2):168–71.

    Article  CAS  PubMed  Google Scholar 

  260. Shelat VG, Seah M, Lim KH. Doxycycline induced acute erosive oesophagitis and presenting as acute dysphagia. J Assoc Physicians India. 2011;59:57–9.

    Google Scholar 

  261. Kato S, Kobayashi M, Sato H, Saito Y, Komatsu K, Harada Y. Doxycycline-induced hemorrhagic esophagitis: a pediatric case. J Pediatr Gastroenterol Nutr. 1988;7(5):762–5.

    Article  CAS  PubMed  Google Scholar 

  262. Amendola MA, Spera TD. Doxycycline-induced esophagitis. JAMA. 1985;253(7):1009–11.

    Article  CAS  PubMed  Google Scholar 

  263. Al Mofarreh MA, Al Mofleh IA. Doxycline-induced esophageal ulcerations. Saudi J Gastroenterol. 1998;4(1):20–4.

    PubMed  Google Scholar 

  264. Tahan V, Sayrak H, Bayar N, Erer B, Tahan G, Dane F. Doxycycline-induced ulceration mimicking esophageal cancer. Cases J. 2008;1(1):144.

    Article  PubMed  PubMed Central  Google Scholar 

  265. Orr LH, Rudisill E, Brodkin R, Hamilton RW. Exacerbation of renal failure associated with doxycycline. Arch Intern Med. 1978;138(5):793–4.

    Article  PubMed  Google Scholar 

  266. Wachira JK, Jensen CH, Rhone K. Doxycycline-induced pancreatitis: a rare finding. S D Med. 2013;66(6):227–9.

    PubMed  Google Scholar 

  267. Ocal S, Selçuk H, Korkmaz M, Unal H, Yilmaz U. Acute pancreatitis following doxycycline and ornidazole coadministration. JOP. 2010;11(6):614–6.

    PubMed  Google Scholar 

  268. Inayat F, Virk HU, Yoon DJ, Riaz I. Drug-induced pancreatitis: a rare manifestation of doxycycline administration. N Am J Med Sci. 2016;8(2):117–20.

    Article  PubMed  PubMed Central  Google Scholar 

  269. Eland IA, van Puijenbroek EP, Sturkenboom MJ, Wilson JH, Stricker BH. Drug-associated acute pancreatitis: twenty-one years of spontaneous reporting in The Netherlands. Am J Gastroenterol. 1999;94(9):2417–22.

    Article  CAS  PubMed  Google Scholar 

  270. Moy BT, Kapila N. Probable doxycycline-induced acute pancreatitis. Am J Health Syst Pharm. 2016;73(5):286–91.

    Article  PubMed  Google Scholar 

  271. Achecar Justo L, Rivero Fernández M, Cobo Reinoso J, Ruiz Del Arbol Olmos L. Doxycycline induced-acute pancreatitis. Med Clin (Barc). 2010;134(15):705–6.

    Article  Google Scholar 

  272. Pourmorteza M, Virk H, Yoon D, Riaz I, Rai A, Rahman Z. P14: doxycycline: a rare cause of drug induced pancreatitis. J Investig Med. 2016;64(3):822–3.

    Google Scholar 

  273. Knox-Macaulay HH, Adil SN, Ahmed EM. Acute thrombotic thrombocytopenic purpura following doxycycline treatment of Chlamydia pneumoniae infection in a patient with dermatomyositis. Clin Lab Haematol. 2004;26(2):147–51.

    Article  CAS  PubMed  Google Scholar 

  274. Chulay JD, Spencer HC, Mugambi M. Electrocardiographic changes during treatment of leishmaniasis with pentavalent antimony (sodium stibogluconate). Am J Trop Med Hyg. 1985;34(4):702–9.

    Article  CAS  PubMed  Google Scholar 

  275. Hepburn NC, Siddique I, Howie AF, Beckett GJ, Hayes PC. Hepatotoxicity of sodium stibogluconate in leishmaniasis. Lancet. 1993;342(8865):238–9.

    Article  CAS  PubMed  Google Scholar 

  276. Hepburn NC, Siddique I, Howie AF, Beckett GJ, Hayes PC. Hepatotoxicity of sodium stibogluconate therapy for American cutaneous leishmaniasis. Trans R Soc Trop Med Hyg. 1994;88(4):453–5.

    Article  CAS  PubMed  Google Scholar 

  277. Oliveira AL, Brustoloni YM, Fernandes TD, Dorval ME, Cunha RV, Bóia MN. Severe adverse reactions to meglumine antimoniate in the treatment of visceral leishmaniasis: a report of 13 cases in the southwestern region of Brazil. Trop Dr. 2009;39(3):180–2.

    Google Scholar 

  278. Neumayr AL, Walter C, Stoeckle M, Braendle N, Glatz K, Blum JA. Successful treatment of imported mucosal Leishmania infantum leishmaniasis with miltefosine after severe hypokalemia under meglumine antimoniate treatment. J Travel Med. 2012;19(2):124–6.

    Article  PubMed  Google Scholar 

  279. Ortega-Carnicer J, Alcázar R, de la Torre M, Benezet J. Pentavalent antimonial-induced torsade de pointes. J Electrocardiol. 1997;30(2):143–5.

    Article  CAS  PubMed  Google Scholar 

  280. Castelló Viguer MT, Echánove Errazti I, Ridocci Soriano F, Esteban Esteban E, Atienza Fernández F, Cuesta Estellés G. Torsades de pointes during treatment of leishmaniasis with meglumine antimoniate. Rev Esp Cardiol. 1999;52(7):533–5.

    Article  PubMed  Google Scholar 

  281. Ezzine Sebai N, Mrabet N, Khaled A, et al. Side effects of meglumine antimoniate in cutaneous leishmaniasis: 15 cases. Tunis Med. 2010;88(1):9–11.

    PubMed  Google Scholar 

  282. Hailu W, Weldegebreal T, Hurissa Z, et al. Safety and effectiveness of meglumine antimoniate in the treatment of Ethiopian visceral leishmaniasis patients with and without HIV co-infection. Trans R Soc Trop Med Hyg. 2010;104(11):706–12.

    Article  CAS  PubMed  Google Scholar 

  283. Rodrigues ML, Costa RS, Souza CS, Foss NT, Roselino AM. Nephrotoxicity attributed to meglumine antimoniate (Glucantime) in the treatment of generalized cutaneous leishmaniasis. Rev Inst Med Trop Sao Paulo. 1999;41(1):33–7.

    Article  CAS  PubMed  Google Scholar 

  284. Samrao A, Berry TM, Goreshi R, Simpson EL. A pilot study of an oral phosphodiesterase inhibitor (apremilast) for atopic dermatitis in adults. Arch Dermatol. 2012;148(8):890–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  285. Aruna AS, Al-Samarrai SA, Al-Humaidan AS. Amphotericin B-induced seizures in a patient with AIDS. Ann Pharmacother. 2001;35(9):1037–41.

    Article  CAS  PubMed  Google Scholar 

  286. Chongtham DS, Singh MM, Ram T. Amphotericin B induced ventricular arrhythmia and its relation to central venous line. J Postgrad Med. 2001;47(4):282.

    CAS  PubMed  Google Scholar 

  287. Thakur CP. Correction of serum electrolyte imbalance prevents cardiac arrhythmia during amphotericin B administration. Natl Med J India. 1995;8(1):13–4.

    CAS  PubMed  Google Scholar 

  288. Craven PC, Gremillion DH. Risk factors of ventricular fibrillation during rapid amphotericin B infusion. Antimicrob Agents Chemother. 1985;27(5):868–71.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  289. Googe JH, Walterspiel JN. Arrhythmia caused by amphotericin B in a neonate. Pediatr Infect Dis J. 1988;7(1):73.

    Article  CAS  PubMed  Google Scholar 

  290. Aguado JM, Hidalgo M, Moya I, Alcazar JM, Jimenez MJ, Noriega AR. Ventricular arrhythmias with conventional and liposomal amphotericin. Lancet. 1993;342(8881):1239.

    Article  CAS  PubMed  Google Scholar 

  291. Sanches BF, Nunes P, Almeida H, Rebelo M. Atrioventricular block related to liposomal amphotericin B. BMJ Case Rep. 2014;2014:bcr2013202688.

    Article  PubMed  PubMed Central  Google Scholar 

  292. Patel GP, Crank CW, Leikin JB. An evaluation of hepatotoxicity and nephrotoxicity of liposomal amphotericin B (L-AMB). J Med Toxicol. 2011;7(1):12–5.

    Article  CAS  PubMed  Google Scholar 

  293. Gill J, Sprenger HR, Ralph ED, Sharpe MD. Hepatotoxicity possibly caused by amphotericin B. Ann Pharmacother. 1999;33(6):683–5.

    Article  CAS  PubMed  Google Scholar 

  294. Miller MA. Reversible hepatotoxicity related to amphotericin B. Can Med Assoc J. 1984;131(10):1245–7.

    CAS  PubMed  PubMed Central  Google Scholar 

  295. Shigemi A, Matsumoto K, Ikawa K, et al. Safety analysis of liposomal amphotericin B in adult patients: anaemia, thrombocytopenia, nephrotoxicity, hepatotoxicity and hypokalaemia. Int J Antimicrob Agents. 2011;38(5):417–20.

    Article  CAS  PubMed  Google Scholar 

  296. Ellis M, Shamoon A, Gorka W, Zwaan F, al-Ramadi B. Severe hepatic injury associated with lipid formulations of amphotericin B. Clin Infect Dis. 2001;32(5):E87–9.

    Article  CAS  PubMed  Google Scholar 

  297. Mohan UR, Bush A. Amphotericin B-induced hepatorenal failure in cystic fibrosis. Pediatr Pulmonol. 2002;33(6):497–500.

    Article  PubMed  Google Scholar 

  298. Shindo K, Mizuno T, Matsumoto Y, et al. Granulocytopenia and thrombocytopenia associated with combination therapy of amphotericin B and low-dose flucytosine in a patient with cryptococcal meningitis. DICP. 1989;23(9):672–4.

    Article  CAS  PubMed  Google Scholar 

  299. Vaidya SJ, Seydel C, Patel SR, Ortin M. Anaphylactic reaction to liposomal amphotericin B. Ann Pharmacother. 2002;36(9):1480–1.

    Article  PubMed  Google Scholar 

  300. Torre I, López-Herce J, Vázguez P. Anaphylactic reaction to liposomal amphotericin B in children. Ann Pharmacother. 1996;30(9):1036–7.

    Article  CAS  PubMed  Google Scholar 

  301. Schneider P, Klein RM, Dietze L, Söhngen D, Leschke M, Heyll A. Anaphylactic reaction to liposomal amphotericin (AmBisome). Br J Haematol. 1998;102(4):1108–9.

    Article  CAS  PubMed  Google Scholar 

  302. Kauffman CA, Wiseman SW. Anaphylaxis upon switching lipid-containing amphotericin B formulations. Clin Infect Dis. 1998;26(5):1237–8.

    Article  CAS  PubMed  Google Scholar 

  303. Laing RB, Milne LJ, Leen CL, Malcolm GP, Steers AJ. Anaphylactic reactions to liposomal amphotericin. Lancet. 1994;344(8923):682.

    Article  CAS  PubMed  Google Scholar 

  304. Nath P, Basher A, Harada M, et al. Immediate hypersensitivity reaction following liposomal amphotericin-B (AmBisome) infusion. Trop Dr. 2014;44(4):241–2.

    Google Scholar 

  305. Moyssakis I, Vassilakopoulos TP, Sipsas NV, et al. Reversible dilated cardiomyopathy associated with amphotericin B treatment. Int J Antimicrob Agents. 2005;25(5):444–7.

    Article  CAS  PubMed  Google Scholar 

  306. Bandeira AC, Filho JM, de Almeida Ramos K. Reversible cardiomyopathy secondary to Amphotericin-B. Med Mycol Case Rep. 2016;13:19–21.

    Article  PubMed  PubMed Central  Google Scholar 

  307. Soares JR, Nunes MC, Leite AF, Falqueto EB, Lacerda BE, Ferrari TC. Reversible dilated cardiomyopathy associated with amphotericin B therapy. J Clin Pharm Ther. 2015;40(3):333–5.

    Article  CAS  PubMed  Google Scholar 

  308. Chung DK, Koenig MG. Reversible cardiac enlargement during treatment with amphotericin B and hydrocortisone. Report of three cases. Am Rev Respir Dis. 1971;103(6):831–41.

    CAS  PubMed  Google Scholar 

  309. Balslev U, Nielsen TL. Adverse effects associated with intravenous pentamidine isethionate as treatment of Pneumocystis carinii pneumonia in AIDS patients. Dan Med Bull. 1992;39(4):366–8.

    CAS  PubMed  Google Scholar 

  310. Stahl-Bayliss CM, Kalman CM, Laskin OL. Pentamidine-induced hypoglycemia in patients with the acquired immune deficiency syndrome. Clin Pharmacol Ther. 1986;39(3):271–5.

    Article  CAS  PubMed  Google Scholar 

  311. Das VN, Ranjan A, Sinha AN, et al. A randomized clinical trial of low dosage combination of pentamidine and allopurinol in the treatment of antimony unresponsive cases of visceral leishmaniasis. J Assoc Physicians India. 2001;49:609–13.

    CAS  PubMed  Google Scholar 

  312. CP L, HP W, Chuang LM, Lin BJ, Chuang CY, Tai TY. Pentamidine-induced hyperglycemia and ketosis in acquired immunodeficiency syndrome. Pancreas. 1995;11(3):315–6.

    Article  Google Scholar 

  313. Bouchard P, Sai P, Reach G, Caubarrère I, Ganeval D, Assan R. Diabetes mellitus following pentamidine-induced hypoglycemia in humans. Diabetes. 1982;31(1):40–5.

    Article  CAS  PubMed  Google Scholar 

  314. Hauser L, Sheehan P, Simpkins H. Pancreatic pathology in pentamidine-induced diabetes in acquired immunodeficiency syndrome patients. Hum Pathol. 1991;22(9):926–9.

    Article  CAS  PubMed  Google Scholar 

  315. Schwartz MS, Cappell MS. Pentamidine-associated pancreatitis. Dig Dis Sci. 1989;34(10):1617–20.

    Article  CAS  PubMed  Google Scholar 

  316. Murphey SA, Josephs AS. Acute pancreatitis associated with pentamidine therapy. Arch Intern Med. 1981;141(1):56–8.

    Article  CAS  PubMed  Google Scholar 

  317. Sauleda J, Gea JG, Aguar MC, Aran X, Pastó M, Broquetas JM. Probable pentamidine-induced acute pancreatitis. Ann Pharmacother. 1994;28(1):52–3.

    Article  CAS  PubMed  Google Scholar 

  318. Klatt EC. Pathology of pentamidine-induced pancreatitis. Arch Pathol Lab Med. 1992;116(2):162–4.

    CAS  PubMed  Google Scholar 

  319. Murphy RL, Noskin GA, Ehrenpreis ED. Acute pancreatitis associated with aerosolized pentamidine. Am J Med. 1990;88(5N):53N–6N.

    CAS  PubMed  Google Scholar 

  320. Herer B, Chinet T, Labrune S, Collignon MA, Chretien J, Huchon G. Pancreatitis associated with pentamidine by aerosol. BMJ. 1989;298(6673):605.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  321. Shen M, Orwoll ES, Conte JE, Prince MJ. Pentamidine-induced pancreatic beta-cell dysfunction. Am J Med. 1989;86(6 Pt 1):726–8.

    Article  CAS  PubMed  Google Scholar 

  322. Briceland LL, Bailie GR. Pentamidine-associated nephrotoxicity and hyperkalemia in patients with AIDS. DICP. 1991;25(11):1171–4.

    Article  CAS  PubMed  Google Scholar 

  323. Lachaal M, Venuto RC. Nephrotoxicity and hyperkalemia in patients with acquired immunodeficiency syndrome treated with pentamidine. Am J Med. 1989;87(3):260–3.

    Article  CAS  PubMed  Google Scholar 

  324. Misíková Z, Kovács L, Foltinová A. Nephrotoxic effect of pentamidine in the treatment of interstitial pneumonia in 2 children with acute lymphoblastic leukemia. Cesk Pediatr. 1979;34(12):715–7.

    PubMed  Google Scholar 

  325. Helmick CG, Green JK. Pentamidine-associated hypotension and route of administration. Ann Intern Med. 1985;103(3):480.

    Article  CAS  PubMed  Google Scholar 

  326. Bibler MR, Chou TC, Toltzis RJ, Wade PA. Recurrent ventricular tachycardia due to pentamidine-induced cardiotoxicity. Chest. 1988;94(6):1303–6.

    Article  CAS  PubMed  Google Scholar 

  327. Mani S, Kocheril AG, Andriole VT. Case report: pentamidine and polymorphic ventricular tachycardia revisited. Am J Med Sci. 1993;305(4):236–40.

    Article  CAS  PubMed  Google Scholar 

  328. Stein KM, Haronian H, Mensah GA, Acosta A, Jacobs J, Kligfield P. Ventricular tachycardia and torsades de pointes complicating pentamidine therapy of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. Am J Cardiol. 1990;66(10):888–9.

    Article  CAS  PubMed  Google Scholar 

  329. Wang JJ, Freeman AI, Gaeta JF, Sinks LF. Unusual complications of pentamidine in the treatment of Pneumocystis carinii pneumonia. J Pediatr. 1970;77(2):311–4.

    Article  CAS  PubMed  Google Scholar 

  330. Watarai A, Niiyama S, Amoh Y, Katsuoka K. Toxic epidermal necrolysis caused by aerosolized pentamidine. Am J Med. 2009;122(1):e1–2.

    Article  PubMed  Google Scholar 

  331. Picon M, Causse X, Gelas P, Retornaz G, Trépo C, Bouletreau P. Pentamidine-related acute hepatitis during pneumocystosis treatment in acquired immunodeficiency syndrome. Gastroenterol Clin Biol. 1991;15(5):463–4.

    CAS  PubMed  Google Scholar 

  332. DeMasi JM, Cox JA, Leonard D, Koh AY, Aquino VM. Intravenous pentamidine is safe and effective as primary pneumocystis pneumonia prophylaxis in children and adolescents undergoing hematopoietic stem cell transplantation. Pediatr Infect Dis J. 2013;32(9):933–6.

    Article  PubMed  Google Scholar 

  333. Caumes E, Bocquet H, Guermonprez G, et al. Adverse cutaneous reactions to pyrimethamine/sulfadiazine and pyrimethamine/clindamycin in patients with AIDS and toxoplasmic encephalitis. Clin Infect Dis. 1995;21(3):656–8.

    Article  CAS  PubMed  Google Scholar 

  334. Bamber MG, Elder AT, Gray JA, Minns RA. Fatal Stevens-Johnson syndrome associated with Fansidar and chloroquine. J Infect. 1986;13(1):31–3.

    Article  CAS  PubMed  Google Scholar 

  335. Pajor A. Pancytopenia in a patient given pyrimethamine and sulphamethoxidiazine during pregnancy. Arch Gynecol Obstet. 1990;247(4):215–7.

    Article  CAS  PubMed  Google Scholar 

  336. Boudes P, Zittoun J, Sobel A. Acute pancytopenia induced by pyrimethamine during treatment of cerebral toxoplasmosis associated with AIDS. Role of dihydrofolate reductase inhibitors. Ann Med Interne (Paris). 1990;141(2):183–6.

    CAS  Google Scholar 

  337. Mori T, Kato J, Okamoto S. Pancytopenia due to pyrimethamine triggered by transplant-associated microangiopathy after allogeneic bone marrow transplantation. J Infect Chemother. 2011;17(6):866–7.

    Article  PubMed  Google Scholar 

  338. Matthews JI, Molitor JT, Hunt KK. Pyrimethamine-induced leukopenia and thrombocytopenia in a patient with malaria and tropical sprue: case report. Mil Med. 1973;138(5):280–3.

    CAS  PubMed  Google Scholar 

  339. Armata J. Letter: pyrimethamine poisoning. Br Med J. 1973;4(5895):783.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  340. Zheng X, Fang X, Cai X. Two episodes of anaphylaxis caused by a chlorhexidine sulfadiazine-coated central venous catheter. Chin Med J. 2014;127(12):2395–7.

    PubMed  Google Scholar 

  341. Stephens R, Mythen M, Kallis P, Davies DW, Egner W, Rickards A. Two episodes of life-threatening anaphylaxis in the same patient to a chlorhexidine-sulphadiazine-coated central venous catheter. Br J Anaesth. 2001;87(2):306–8.

    Article  CAS  PubMed  Google Scholar 

  342. Boyette DP, London AH. Hemolytic anemia due to sulfadiazine; report of a case. N C Med J. 1949;10(3):132.

    CAS  PubMed  Google Scholar 

  343. Ross JF, Paegel BL. Acute hemolytic anemia and hemoglobinuria following sulfadiazine medication. Blood. 1946;1:189–201.

    CAS  PubMed  Google Scholar 

  344. Eldad A, Neuman A, Weinberg A, Benmeir P, Rotem M, Wexler MR. Silver sulphadiazine-induced haemolytic anaemia in a glucose-6-phosphate dehydrogenase-deficient burn patient. Burns. 1991;17(5):430–2.

    Article  CAS  PubMed  Google Scholar 

  345. Khalili H, Soudbakhsh A, Talasaz AH. Severe hepatotoxicity and probable hepatorenal syndrome associated with sulfadiazine. Am J Health Syst Pharm. 2011;68(10):888–92.

    Article  CAS  PubMed  Google Scholar 

  346. Geier B, Nousbaum JP, Cauvin JM, Rosaszkiewick M, Gouérou H. Acute hepatitis probably secondary to the treatment with pyrimethamine-sulfadiazine combination. Gastroenterol Clin Biol. 1992;16(8–9):724–5.

    CAS  PubMed  Google Scholar 

  347. Díaz F, Collazos J, Mayo J, Martínez E. Sulfadiazine-induced multiple urolithiasis and acute renal failure in a patient with AIDS and Toxoplasma encephalitis. Ann Pharmacother. 1996;30(1):41–2.

    Article  PubMed  Google Scholar 

  348. Chaby G, Viseux V, Poulain JF, De Cagny B, Denoeux JP, Lok C. Topical silver sulfadiazine-induced acute renal failure. Ann Dermatol Venereol. 2005;132(11 Pt 1):891–3.

    Article  CAS  PubMed  Google Scholar 

  349. de la Prada Alvarez FJ, Prados Gallardo AM, Tugores Vázquez A, Uriol Rivera M, Morey Molina A. Acute renal failure due to sulfadiazine crystalluria. An Med Interna. 2007;24(5):235–8.

    PubMed  Google Scholar 

  350. Hein R, Brunkhorst R, Thon WF, Schedel I, Schmidt RE. Symptomatic sulfadiazine crystalluria in AIDS patients: a report of two cases. Clin Nephrol. 1993;39(5):254–6.

    CAS  PubMed  Google Scholar 

  351. Simon DI, Brosius FC, Rothstein DM. Sulfadiazine crystalluria revisited. The treatment of Toxoplasma encephalitis in patients with acquired immunodeficiency syndrome. Arch Intern Med. 1990;150(11):2379–84.

    Article  CAS  PubMed  Google Scholar 

  352. Oster S, Hutchison F, McCabe R. Resolution of acute renal failure in toxoplasmic encephalitis despite continuance of sulfadiazine. Rev Infect Dis. 1990;12(4):618–20.

    Article  CAS  PubMed  Google Scholar 

  353. Guitard J, Kamar N, Mouzin M, et al. Sulfadiazine-related obstructive urinary tract lithiasis: an unusual cause of acute renal failure after kidney transplantation. Clin Nephrol. 2005;63(5):405–7.

    Article  CAS  PubMed  Google Scholar 

  354. Jennings LJ, Hanumadass M. Silver sulfadiazine induced clostridium difficile toxic megacolon in a burn patient: case report. Burns. 1998;24(7):676–9.

    Article  CAS  PubMed  Google Scholar 

  355. Tan CB, Rajan D, Shah M, et al. Toxic megacolon from fulminant clostridium difficile infection induced by topical silver sulphadiazine. BMJ Case Rep. 2012;2012:bcr2012006460.

    PubMed  PubMed Central  Google Scholar 

  356. Arnold HL. Lupus erythematosus disseminatus (response to sulfadiazine?). Arch Dermatol Syphilol. 1946;53:53.

    Article  Google Scholar 

  357. Tsai TC, Peng SK, Shih YR, Luk HN. Sulfadiazine-induced methemoglobinemia in a boy with thalassemia. Can J Anaesth. 2005;52(9):1002–3.

    Article  PubMed  Google Scholar 

  358. Kath MA, Shupp JW, Matt SE, et al. Incidence of methemoglobinemia in patients receiving cerium nitrate and silver sulfadiazine for the treatment of burn wounds: a burn center’s experience. Wound Repair Regen. 2011;19(2):201–4.

    Article  PubMed  Google Scholar 

  359. Taqi SA, Zaki SA, Nilofer AR, Sami LB. Trimethoprim-sulfamethoxazole-induced Steven Johnson syndrome in an HIV-infected patient. Indian J Pharmacol. 2012;44(4):533–5.

    Article  PubMed  PubMed Central  Google Scholar 

  360. Langlois MR, Derk F, Belczyk R, Zgonis T. Trimethoprim-sulfamethoxazole-induced Stevens-Johnson syndrome: a case report. J Am Podiatr Med Assoc. 2010;100(4):299–303.

    Article  PubMed  Google Scholar 

  361. Mistry RD, Schwab SH, Treat JR. Stevens-Johnson syndrome and toxic epidermal necrolysis: consequence of treatment of an emerging pathogen. Pediatr Emerg Care. 2009;25(8):519–22.

    Article  PubMed  Google Scholar 

  362. Muñoz SJ, Martinez-Hernandez A, Maddrey WC. Intrahepatic cholestasis and phospholipidosis associated with the use of trimethoprim-sulfamethoxazole. Hepatology. 1990;12(2):342–7.

    Article  PubMed  Google Scholar 

  363. Abusin S, Johnson S. Sulfamethoxazole/trimethoprim induced liver failure: a case report. Cases J. 2008;1(1):44.

    Article  PubMed  PubMed Central  Google Scholar 

  364. Faria LC, Resende CC, Couto CA, Couto OF, Fonseca LP, Ferrari TC. Severe and prolonged cholestasis caused by trimethoprim-sulfamethoxazole: a case report. Clinics (Sao Paulo). 2009;64(1):71–4.

    Article  Google Scholar 

  365. Colucci CF, Lo Cicero M. Letter: hepatic necrosis and trimethoprim-sulfamethoxazole. JAMA. 1975;233(9):952–3.

    Article  CAS  PubMed  Google Scholar 

  366. Alberti-Flor JJ, Hernandez ME, Ferrer JP, Howell S, Jeffers L. Fulminant liver failure and pancreatitis associated with the use of sulfamethoxazole-trimethoprim. Am J Gastroenterol. 1989;84(12):1577–9.

    CAS  PubMed  Google Scholar 

  367. Andrès E, Noel E, Maloisel F. Trimethoprim-sulfamethoxazole-induced life-threatening agranulocytosis. Arch Intern Med. 2003;163(16):1975–6. author reply 1976

    Article  PubMed  Google Scholar 

  368. Jha P, Stromich J, Cohen M, Wainaina JN. A rare complication of trimethoprim-sulfamethoxazole: drug induced aseptic meningitis. Case Rep Infect Dis. 2016;2016:3879406.

    PubMed  PubMed Central  Google Scholar 

  369. Keisu M, Wiholm BE, Palmblad J. Trimethoprim-sulphamethoxazole-associated blood dyscrasias. Ten years’ experience of the Swedish spontaneous reporting system. J Intern Med. 1990;228(4):353–60.

    Article  CAS  PubMed  Google Scholar 

  370. Menger RP, Dossani RH, Thakur JD, Farokhi F, Morrow K, Guthikonda B. Extra-axial hematoma and trimethoprim-sulfamethoxazole induced aplastic anemia: the role of hematological diseases in subdural and epidural hemorrhage. Case Rep Hematol. 2015;2015:374951.

    PubMed  PubMed Central  Google Scholar 

  371. Bartels RH, van der Spek JA, Oosten HR. Acute pancreatitis due to sulfamethoxazole-trimethoprim. South Med J. 1992;85(10):1006–7.

    Article  CAS  PubMed  Google Scholar 

  372. Park TY, Oh HC, Do JH. A case of recurrent pancreatitis induced by trimethoprim-sulfamethoxazole re-exposure. Gut Liver. 2010;4(2):250–2.

    Article  PubMed  PubMed Central  Google Scholar 

  373. Antonow DR. Acute pancreatitis associated with trimethoprim-sulfamethoxazole. Ann Intern Med. 1986;104(3):363–5.

    Article  CAS  PubMed  Google Scholar 

  374. Dickey SE, Mabry WA, Hamilton LA. Possible sulfamethoxazole/trimethoprim-induced pancreatitis in a complicated adolescent patient posttraumatic injury. J Pharm Pract. 2015;28(4):419–24.

    Article  PubMed  Google Scholar 

  375. Floris-Moore MA, Amodio-Groton MI, Catalano MT. Adverse reactions to trimethoprim/sulfamethoxazole in AIDS. Ann Pharmacother. 2003;37(12):1810–3.

    Article  PubMed  Google Scholar 

  376. Versleijen MW, Naber AH, Riksen NP, Wanten GJ, Debruyne FM. Recurrent pancreatitis after trimethoprim-sulfamethoxazole rechallenge. Neth J Med. 2005;63(7):275–7.

    CAS  PubMed  Google Scholar 

  377. Garvey JP, Brown CM, Chotirmall SH, Dorman AM, Conlon PJ, Walshe JJ. Trimethoprim-sulfamethoxazole induced acute interstitial nephritis in renal allografts; clinical course and outcome. Clin Nephrol. 2009;72(5):331–6.

    Article  CAS  PubMed  Google Scholar 

  378. Fraser TN, Avellaneda AA, Graviss EA, Musher DM. Acute kidney injury associated with trimethoprim/sulfamethoxazole. J Antimicrob Chemother. 2012;67(5):1271–7.

    Article  CAS  PubMed  Google Scholar 

  379. Smith EJ, Light JA, Filo RS, Yum MN. Interstitial nephritis caused by trimethoprim-sulfamethoxazole in renal transplant recipients. JAMA. 1980;244(4):360–1.

    Article  CAS  PubMed  Google Scholar 

  380. Cryst C, Hammar SP. Acute granulomatous interstitial nephritis due to co-trimoxazole. Am J Nephrol. 1988;8(6):483–8.

    Article  CAS  PubMed  Google Scholar 

  381. Kawasumi H, Tanaka E, Hoshi D, Kawaguchi Y, Yamanaka H. Methemoglobinemia induced by trimethoprim-sulfamethoxazole in a patient with systemic lupus erythematosus. Intern Med. 2013;52(15):1741–3.

    Article  PubMed  Google Scholar 

  382. Carroll TG, Carroll MG. Methemoglobinemia in a pediatric oncology patient receiving sulfamethoxazole/trimethoprim prophylaxis. Am J Case Rep. 2016;17:499–502.

    Article  PubMed  PubMed Central  Google Scholar 

  383. Koirala J. Trimethoprim-sulfamethoxazole—induced methemoglobinemia in an HIV-infected patient. Mayo Clin Proc. 2004;79(6):829–30.

    Article  PubMed  Google Scholar 

  384. Damergis JA, Stoker JM, Abadie JL. Methemoglobinemia after sulfametoxazole and trimethoprim. JAMA. 1983;249(5):590–1.

    Article  CAS  PubMed  Google Scholar 

  385. Bruner KE, Coop CA, White KM. Trimethoprim-sulfamethoxazole-induced aseptic meningitis-not just another sulfa allergy. Ann Allergy Asthma Immunol. 2014;113(5):520–6.

    Article  CAS  PubMed  Google Scholar 

  386. Naitoh T, Yamamoto M, Kawakami K, et al. Case of systemic lupus erythematosus repeated with various allergic reactions by trimethoprim-sulfamethoxazole. Nihon Rinsho Meneki Gakkai Kaishi. 2009;32(6):492–8.

    Article  PubMed  Google Scholar 

  387. Jose A, Cramer AK, Davar K, Gutierrez G. A case of drug-induced lupus erythematosus secondary to trimethoprim/sulfamethoxazole presenting with pleural effusions and pericardial tamponade. Lupus. 2016;

    Google Scholar 

  388. Gordin F, Gibert C, Schmidt ME. Clostridium difficile colitis associated with trimethoprim-sulfamethoxazole given as prophylaxis for Pneumocystis carinii pneumonia. Am J Med. 1994;96(1):94–5.

    Article  CAS  PubMed  Google Scholar 

  389. Ainapurapu B, Kanakadandi UB. Trimethoprim-sulfamethoxazole induced rhabdomyolysis. Am J Ther. 2014;21(3):e78–9.

    Article  PubMed  Google Scholar 

  390. Kiel PJ, Dickmeyer N, Schwartz JE. Trimethoprim-sulfamethoxazole-induced rhabdomyolysis in an allogeneic stem cell transplant patient. Transpl Infect Dis. 2010;12(5):451–4.

    Article  CAS  PubMed  Google Scholar 

  391. Walker S, Norwood J, Thornton C, Schaberg D. Trimethoprim-sulfamethoxazole associated rhabdomyolysis in a patient with AIDS: case report and review of the literature. Am J Med Sci. 2006;331(6):339–41.

    Article  PubMed  Google Scholar 

  392. Augustyn A, Lisa Alattar M, Naina H. Rhabdomyolysis due to trimethoprim-sulfamethoxazole administration following a hematopoietic stem cell transplant. Case Rep Oncol Med. 2015;2015:619473.

    PubMed  PubMed Central  Google Scholar 

  393. Singer SJ, Racoosin JA, Viraraghavan R. Rhabdomyolysis in human immunodeficiency virus—positive patients taking trimethoprim-sulfamethoxazole. Clin Infect Dis. 1998;26(1):233–4.

    Article  CAS  PubMed  Google Scholar 

  394. Mancano MA. Trimethoprim-sulfamethoxazole-induced rhabdomyolysis; gabapentin-induced hypoglycemia in diabetic and nondiabetic patients; purple glove syndrome after oral phenytoin administration; acute dystonic reaction after methylphenidate initiation; serotonin syndrome with vilazodone monotherapy; cabozantinib-associated dermatologic adverse reactions. Hosp Pharm. 2015;50(8):662–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  395. Cottle LE, Peters JR, Hall A, et al. Multiorgan dysfunction caused by travel-associated African trypanosomiasis. Emerg Infect Dis. 2012;18(2):287–9.

    Article  PubMed  PubMed Central  Google Scholar 

  396. Awadzi K. Clinical picture and outcome of serious adverse events in the treatment of onchocerciasis. Filaria J. 2003;2(Suppl 1):S6.

    Article  PubMed  PubMed Central  Google Scholar 

  397. Smith A, Harbour D, Liebmann J. Acute renal failure in a patient receiving treatment with suramin. Am J Clin Oncol. 1997;20(4):433–4.

    Article  CAS  PubMed  Google Scholar 

  398. Thylefors B, Rolland A. The risk of optic atrophy following suramin treatment of ocular onchocerciasis. Bull World Health Organ. 1979;57(3):479–80.

    CAS  PubMed  PubMed Central  Google Scholar 

  399. Arroz JO. Melarsoprol and reactive encephalopathy in Trypanosoma brucei rhodesiense. Trans R Soc Trop Med Hyg. 1987;81(2):192.

    Article  CAS  PubMed  Google Scholar 

  400. Pépin J, Milord F, Khonde AN, et al. Risk factors for encephalopathy and mortality during melarsoprol treatment of Trypanosoma brucei gambiense sleeping sickness. Trans R Soc Trop Med Hyg. 1995;89(1):92–7.

    Article  PubMed  Google Scholar 

  401. Pialoux G, Kernbaum S, Vachon F. Arsenical-induced encephalopathy during the treatment of African trypanosomiasis. Apropos of a case with a favorable outcome. Bull Soc Pathol Exot Filiales. 1988;81(3 Pt 2):555–6.

    CAS  PubMed  Google Scholar 

  402. Blum J, Nkunku S, Burri C. Clinical description of encephalopathic syndromes and risk factors for their occurrence and outcome during melarsoprol treatment of human African trypanosomiasis. Tropical Med Int Health. 2001;6(5):390–400.

    Article  CAS  Google Scholar 

  403. Haller L, Adams H, Merouze F, Dago A. Clinical and pathological aspects of human African trypanosomiasis (T. b. gambiense) with particular reference to reactive arsenical encephalopathy. Am J Trop Med Hyg. 1986;35(1):94–9.

    Article  CAS  PubMed  Google Scholar 

  404. Kuepfer I, Schmid C, Allan M, et al. Safety and efficacy of the 10-day melarsoprol schedule for the treatment of second stage Rhodesiense sleeping sickness. PLoS Negl Trop Dis. 2012;6(8):e1695.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  405. Milord F, Pépin J, Loko L, Ethier L, Mpia B. Efficacy and toxicity of eflornithine for treatment of Trypanosoma brucei gambiense sleeping sickness. Lancet. 1992;340(8820):652–5.

    Article  CAS  PubMed  Google Scholar 

  406. Forsyth CJ, Hernandez S, Olmedo W, et al. Safety profile of nifurtimox for treatment of chagas disease in the United States. Clin Infect Dis. 2016;63(8):1056–62.

    Article  PubMed  PubMed Central  Google Scholar 

  407. Jackson Y, Alirol E, Getaz L, Wolff H, Combescure C, Chappuis F. Tolerance and safety of nifurtimox in patients with chronic chagas disease. Clin Infect Dis. 2010;51(10):e69–75.

    Article  CAS  PubMed  Google Scholar 

  408. Sundar S, Jha TK, Thakur CP, Sinha PK, Bhattacharya SK. Injectable paromomycin for Visceral leishmaniasis in India. N Engl J Med. 2007;356(25):2571–81.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Assistant Professor of Dermatology at UCLA, Los Angeles, CA, USA

    Scott Worswick MD

  2. MS4 at David Geffen School of Medicine at UCLA, Los Angeles, CA, USA

    Sean Dreyer BA

Authors
  1. Scott Worswick MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sean Dreyer BA
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Scott Worswick MD .

Editor information

Editors and Affiliations

  1. Division of Dermatology, David Geffen School of Medicine a UCLA, Los Angeles, California, USA

    Paul S. Yamauchi

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Worswick, S., Dreyer, S. (2018). Anthelmintics in Dermatology. In: Yamauchi, P. (eds) Biologic and Systemic Agents in Dermatology. Springer, Cham. https://doi.org/10.1007/978-3-319-66884-0_42

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-66884-0_42

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-66883-3

  • Online ISBN: 978-3-319-66884-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation